Alanine-aminotransferase: An early marker for insulin resistance?

Medicina

Volumn 67, Issue 2, 2007, Pages 125-130

  Salazar, Martin R ^a,d   Carbajal, Horacio A ^a   Curciarello, Jose O ^c   Aizpurua, Marcelo ^b   Adrover, Raul E ^c   Riondet, Beatriz ^a  

^a Ministerio de Salud   (Argentina)

^b Hospital Municipal de Rauch   (Argentina)

^c Fundación para el Estudio de las Enfermedades   (Argentina)

^d NONE   (Argentina)

Author keywords

Alanine aminotransferase; Insulin resistance; Metabolic syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PATIENT SELECTION; POPULATION RESEARCH; PREDICTION; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIVER; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SEX DISTRIBUTION; SEX FACTORS;

EID: 34249672735     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Cause of cryptogenic cirrhosis. JAMA 2003; 289: 3000-4.
2. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver Disease. CMA J 2005; 172: 899-905.
3. Bloomgarden ZT. Second World Congress on the Insulin Resistance Syndrome. Insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care 2005; 28: 1518-23.
4. Stranges S, Trevisan M, Dorn JM, Dmochowski J, Donahue RP. Body Fat distribution, liver enzymes, and Risk of hypertension. Evidence from the Western New York Study. Hypertension 2005; 46: 1186-93.
5. Nannipieri M, Gonzales C, Baldi S, et al. Liver enzymes, the metabolic syndrome, and incident diabetes. The Mexico City Diabetes Study. Diabetes Care 2005; 28: 1757-62.
6. Lee DH, Ha MH, Kim JH, et al. Gamma-glutamyltransferase and diabetes: a 4 year follow-up study. Diabeto-logia 2003; 46: 359-64.
7. Nakanishi N, Suzuki K, Tatara K. Serum γ-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004; 27: 1427-32.
8. Lee DH, Silventoinen K, Jacobs DR, Jousilahti P, Tuomileto J. Gamma glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 2004; 89: 5410-4.
9. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of Type 2 diabetes in older men. Diabetes Care 2005; 28: 2913-8.
10. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001; 38: 263-355.
11. Sillanaukee P, Massot N, Jousilahti P, et al. Dose response of laboratory markers to alcohol consumption in a general population. Am J Epidemiol 2000; 152: 747-51.
12. Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51: 1889-95.
13. Sattar N, Scherbakova O, Ford I, et al. The West of Scotland Coronary Prevention Study: Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes 2004; 53: 2855-60.
14. Erbey JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med 2000; 109: 588-90.
15. Hanley AJG, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: The Insulin Resistance Atherosclerosis Study. Diabetes 2004; 53: 2623-32.
16. Stranges S, Dorn JM, Muti P, et al. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology 2004; 39: 754-63.
17. Hanley AJG, Williams K, Festa A, Wagenknecht LA, D'Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: The Insulin Resistance Atherosclerosis Study. Diabetes 2005; 54: 3140-7.
18. Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634-42.
19. Ardigo D, Numeroso F, Valtuena S, et al. Hyperinsulinemia predicts hepatic fat content in healthy individuals with normal transaminase concentrations. Metabolism 2005; 54: 1566-70.
20. Donati G, Stagni B, Piscaglia F, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004; 53: 1020-3.
21. Angelico F, Del Ben M, Conti R, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver Disease. J Clin Endocrinol Metab 2005; 90: 1578-82.
22. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA-IR modeling. Diabetes Care 2004; 27: 1487-95.
23. Reaven G. Metabolic Syndrome. Pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286-8.
24. Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991; 43: 26-31.
25. Saverymuttu S, Joseph A, Maxwell J. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 1986; 292: 13-5.
26. Joy D, Thava VR, Scout BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003; 15: 539-43.
27. Carbajal HA, Salazar MR, Riondet B, et al. Variables asociadas a hipertensión arterial en una región de la Argentina. Medicina (Buenos Aires) 2001; 61: 801-9.
28. Salazar MR, Carbajal HA, Aizpurúa M, et al. Decrease of blood pressure by community-based strategies. Medicina (Buenos Aires) 2005; 65: 507-12.
29. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-9.
30. Kerner A, Avizohar O, Sella R, et al. Association between elevated liver enzymes and C-reactive protein: Possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005; 25: 193-7.
31. Lautt WW. A new paradigm for diabetes and obesity: The Hepatic Insulin Sensitizing Substance (HISS) Hypothesis. J Pharmacol Sci 2004; 95: 9-17.
32. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome- a new worldwide definition. Lancet 2005; 366: 1059-62
33. Reaven GM. The metabolic syndrome: Requiescat in pace. Clin Chem 2005; 51: 931-8.
34. Sternlieb I. Perspectives on Wilson's disease. Hepatology 1990; 12: 1234-9.
35. Leggett BA, Halliday JW, Brown NN, Bryant JJ, Duplock L. Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol 1990; 74: 525-30.
36. Simon M, Brissot P. The genetics of haemochromatosis. J Hepatol 1988; 6: 116-24.
37. Adams PC, Gregor JC, Kertesz AE, Valberg LS. Screening blood donors for hereditary haemochromatosis: decision analysis model based on a 30-year database. Gastroenterology 1995; 109: 177-88.
38. Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 2004; 110: 803-9.
39. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: Prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002; 25: 1135-41.
40. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997; 96: 2520-5.
41. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. High Triglycerides and low HDL cholesterol and blood pressure and risk of ischemic heart disease. Hyper-tension 2000; 36: 226-32.
42. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 2001; 161: 361-6.
43. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven GM. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139: 802-9.